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Abstract 
Immunotherapy using mucin 1 (MUC1) linked to oxidised mannan (MFP) was investigated in an 
aggressive MUC1+ metastatic tumour, DA3-MUC1 because, unlike many MUC1+ tumour models, 
DA3-MUC1 is not spontaneously rejected in mice making it an alternative model for immunothe-
rapy studies. Further, DA3-MUC1 cells are resistant to lysis by anti-MUC1 cytotoxic T cells 
(CTLs). The inability of DA3-MUC1 tumours to be rejected in naïve mice as well as vaccination to 
MUC1 was attributed to a deficiency of expression of MHC class I molecules on the tumour cell 
surface. In vitro and in vivo analysis of subcutaneous tumours and lung metastases demonstrated that 
DA3-MUC1 tumour cells have a low expression (< 6%) of MHC class I which can be upregulated 
(> 90%) following culturing with IFN-γ. Results from flow cytometry analysis and immuno-
peroxidase staining indicated that the in vitro up-regulation of MHC class I could be maintained for 
up to seven days in vivo, without affecting the expression levels of MUC1 antigen. Interestingly, 
MUC1-specific CTL that lyse DA3-MUC1 targets in vitro were induced in MFP immunised mice 
but failed to protect mice from a DA3-MUC1 tumour challenge. These results highlight the impor-
tance of MHC class I molecules in the induction of anti-tumour immunity and the MFP immune 
response. 
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Introduction 
Anti-tumour immunity and tumour eradi-
cation are induced by cell-mediated immune 
responses [1, 2]. The activation of tumour-spe-
cific CD8+ T lymphocytes and their subsequent 
differentiation into cytolytic cells is dependent 
on 2 signals from the antigen-presenting cell. 
One signal is provided through the interaction 
of the antigenic peptide (from the tumour) pre-
sented on the major histocompatibility complex 
(MHC) to T cells. The other is the costimula-
tory signals, efficiently provided by B7 [B7-1 
(CD80) and B7-2 (CD86)] binding to CD28 
(CD152 or CTLA-4) on T cells [3, 4]. Howe-
ver, malignant cells have evolved mechanisms 
enabling them to successfully evade the im-
mune system, which in many cases directly af-
fects this 2 signal process. These mechanisms 
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include inadequate expression of costimulatory 
molecules, Fas ligand, or adhesion molecules 
on cancer cells, antigen processing defects, the 
secretion of inhibitory molecules into the tu-
mour microenvironment or absent or poorly ex-
pressed MHC molecules on the tumour cell 
surface [5–7]. More recently, it has been de-
monstrated that tumour cells have additional 
escape mechanisms by expressing PD-L1 (B7-
H1, CD275) and/or PD-L2 on their surface, 
which upon binding to its ligand, PD-1, expres-
sed by activated CD8+ T cells leads to apop-
tosis of T cells [8]. 
The failure of tumours to adequately 
process antigens and present peptide fragments 
to T cells is greatly attributed to reduced ex-
pression of MHC class I molecules on the cell 
surface of tumour cells [5, 6, 9, 10]. In many 
tumour models however, this can be rectified 
transfecting tumour cells with MHC class I 
gene [11, 12]. Another approach is to transfect 
cytokine cDNA, in particular IFN-γ, into tu-
mours as it directly causes an up-regulation of 
cell surface MHC class I expression [11, 13].  
This study characterises the DA3-MUC1 
metastatic tumour following the failure of man-
nan-MUC1 (MFP) immunisations to induce 
anti-tumour immunity in this MUC1+ cancer 
model. It was demonstrated that DA3-MUC1 
was non-immunogenic due to an absence of 
MHC class I expression on the tumour cell sur-
face, which could be upregulated by IFN-γ but 
not sustained long enough in vivo to cause 
tumour eradication. 
 
Materials and methods 
Mice and immunisations 
A MUC1-GST fusion protein containing 
5 variable number of tandem repeat (VNTR) 
regions from the extracellular protein core of 
MUC1 [14] was produced in a bacterial 
expression system (pGEX-3X) and conjugated 
to oxidised mannan to form MFP as described 
previously [15–23]. BALB/c mice aged 6–10 
weeks were given three intraperitoneal immu-
nisations (on days 0, 7 and 14) with either MFP 
(containing 5μg of MUC1 fusion protein) or a 
control pH 9.0 phosphate buffer. BALB/c mice 
immunised with mannan coupled to oxidised 
GST (M-GST) were included as controls in the 
lung metastases study. All experiments were 
approved by the Austin Animal Ethics Com-
mittee. 
 
Cell lines 
DA3-MUC1 is a metastatic BALB/c 
DA3 mammary cell line transfected with the 
cDNA of the transmembrane form of human 
MUC1 [24, 25]; P815-MUC-1, a DBA/2 P815 
mastocytoma cell lines transfected with the 
cDNA of the transmembrane form of human 
MUC1 [26, 27] were cultured in RPMI and 
MUC1 expression selected for every 14–20 
days with 1.25 mg/ml G418-sulfate (Gibco 
BRL, U.S.A). 
 
Flow cytometry 
The expression of cell surface molecules 
on DA3-MUC1 were measured by flow cyto-
metry. The following monoclonal antibodies 
were used; a) MUC1 (BC2: supernatant) [28], 
b) MHC class 1 H2d (34.1.2s, 1/1000 dilution 
of ascites fluid) [29], c) MHC class II I-A8 
(1/500 dilution of ascites fluid), d) B7.1 (4μg) 
(Pharmingen, San Diego, USA), e) ICAM-2 
(1μg) (Pharmingen), f) CD28 (4μg) (Pharmin-
gen), g) LFA-2 (1μg) (Pharmingen) and h) 
CTLA-4 (1μg) (Pharmingen). DA3-MUC1 tu-
mour cells were prepared for FACS analysis by 
either a) culturing in growth media, b) cultu-
ring with 20 ng/ml vaccinia virus-IFN-γ [22] 
for 72 h, or c) culturing with 20 ng/ml IFN-γ 
for 72 h and then removing IFN-γ for subse-
quent culturing. In preparation for flow cyto-
metry, tumour cells (2–5 x 105 cells/ml) were 
incubated with the specified antibodies for 45 
min at 40C, washed with phosphate buffer and 
incubated with either FITC-conjugated sheep 
(Fab’)2 anti-mouse, anti-rat or anti-hamster im-
munoglobulin (Amersham, UK) (1/50 dilution) 
for a further 45 min at 40C. Cells were washed 
and analysed by flow cytometry. 
 
Immunoperoxidase staining  
of DA3-MUC1 tumour cells 
Cell surface expression of MUC1 and 
MHC class I proteins on DA3-MUC1 tumour 
cells in vivo were analysed by immunopero-
xidase staining. DA3-MUC1 tumour cells were 
either, a) injected subcutaneously into BALB/c 
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mice and grown for > 30 days to establish lung 
metastasis. Mice were culled and samples taken 
from both the subcutaneous tumour site and 
from lung metastasis; or b) cultured with 20 
ng/ml IFN-γ for 72 h and injected subcutaneou-
sly into BALB/c mice. Mice were culled and 
samples taken from the subcutaneous tumour 
site on days 4 and 7 and from lung metastasis > 
30 days after injection.  
All tissue samples were snap frozen in 
isopentane and sections 5–6 μm thick were cut 
using a Microm HM500 cryostat (MICROM 
Laborgerate, Strässe, Germany), mounted and 
fixed on silane coated slides [30]. Endogenous 
peroxidase activity was blocked by incubating 
with 0.5% H2O2 for 40 minutes at room tem-
perature. Tissue sections were incubated for 45 
min at 40C with biotinylated BC2 to detect 
MUC1 expression or biotinylated anti-H2d 
(1/1000 dilution) to detect MHC class I expres-
sion. Excess antibodies were removed by tho-
rough washing and samples incubated with 
streptavidin-HRP conjugate (Amersham, UK) 
(1/50 dilution) for a further 45 min at 40C. An-
tibody binding was detected with 1.5 mg/ml 3–
3 diaminobenzidine (DAB, Sigma, St. Louis, 
USA) in phosphate buffered saline containing 
0.5% H2O2 for 5 min, slides were washed and 
mounted. 
 
Tumour model 
The immunogenicity of DA3-MUC1 tu-
mour was characterised using the following 
tumour growth experiments and MFP immuni-
sations.  
(i) BALB/c mice (x 10) were subcutane-
ously injected with 5 x 106 DA3-MUC1 tu-
mour cells and tumour growth measured with 
electronic callipers every week for 10 weeks to 
establish a DA3-MUC1 growth curve. Mice 
were sacrificed > 30 days after the tumour 
challenge and lung metastasis determined by 
microscopically counting the number of metas-
tasis present in random cross sections of simi-
lar sizes from formalin fixed lung samples 
(Anatomical Pathology Unit, Austin and Repa-
triation Medical Centre, VIC Australia).  
(ii) BALB/c mice (x 20 per group) were 
immunised 3 times on days 0, 7 and 14 with 
either MFP (5 μg) or M-GST (5 μg) and chal-
lenged with 5 x 106 subcutaneous DA3-MUC1 
tumour cells. A minimum of 4 mice from each 
group were sacrificed each week for five weeks 
and the number of metastatic lesions present on 
each lung determined microscopically. 
(iii) BALB/c mice (x 10 per group) were 
injected subcutaneously with 5 x 106 DA3-
MUC1 tumour cells until tumours of ~50 mm2 
were established (Day 17). Mice were then im-
munised intraperitoneally on days 17, 19 and 
21 with 5 μg MFP. Tumour sizes were measu-
red every 2–3 days for 30 days using electronic 
callipers. 
(iv) BALB/c mice (x 10 per group) were 
immunised intraperitoneally on days 0, 7 and 
14 with either 5 μg MFP or pH 9.0 buffer, and 
challenged subcutaneously on day 21 with 3 x 
106 DA3-MUC1 tumour cells. Prior to chal-
lenge, the tumour cells were cultured with 20 
ng/ml vaccinia virus-IFNγ supernatant (UV 
inactivated) [22, 23, 25, 26] for 72 h to increase 
cell surface MHC class I expression. Tumour 
growth was measured every 2–3 days for 2 
weeks using electronic callipers. 
 
Cytotoxic T cell 51Cr release assay 
BALB/c mice immunised (x 3) with MFP 
(5 μg) were culled and their spleen cells colle-
cted and treated with 0.83% NH4Cl. Two-fold 
serial dilutions of effector spleen cells from the 
immunised mice were plated into a 96 well 
plate beginning at a concentration of 1 x 106 
cells per well in duplicate. 1 x 104 51Cr labelled 
DA3-MUC1 cells cultured with IFN-γ (20 
ng/ml) for 72 h, DA3-MUC1, P815-MUC1 or 
P815 target cells were added to the effectors. 
The spontaneous release of 51Cr from the label-
led cells was determined by incubating target 
cells in RPMIM media and the maximum re-
lease was determined by incubation with 10% 
SDS (BDH Chemicals, Dorset, England). Cul-
tures were incubated for 4 h before transferring 
100 μl of supernatant to 96 well flat Optiplates 
(Disposable Products, Australia) containing 
100 μl of Microscint 40 (Packard, USA) for 
analysis on the microplate scintillation counter 
(Packard USA). The specific percentage lysis 
of target cells was determined by; [(experimen-
tal-spontaneous) cpm / (maximum-spontaneous) 
cpm] x 100%. 
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Results 
Immunisation which does not protect 
against DA3-MUC1 tumour growth 
To examine the anti-tumour effects of 
MFP immunisations on the DA3-MUC1 tumour 
in vivo, 2 immunotherapy models were used.  
In the first model, BALB/c mice with an 
established DA3-MUC1 tumour (~50 mm2) 
were immunised 3 times (days 17, 19 and 21) 
with either MFP or control pH 9.0 buffer, and, 
tumour growth and lung metastases measured 
for 30 days. Unlike other tumour models [30] 
in the DA3-MUC1 model, there was no diffe-
rence in tumour growth (Figure 1A) or the 
number of lung metastases (as determine by 
lung weight) (data not shown). Therefore, 
therapy with MFP was not effective at treating 
established DA3-MUC1 tumours. 
 
 
 
 
Figure 1. A – Subcutaneous DA3-MUC1 (5 x 106 
cells/mouse) tumour growth in BALB/c mice immunised 
with MFP. Mice with an established 17 day tumour were 
immunised intraperitoneally on days 17, 19 and 21 with 
5 μg MFP or pH 9.0 buffer and tumour growth 
measured. B. Lung metastases in BALB/c mice 
immunised with either MFP or a control M-GST 3 times 
(days 0, 7 and 14), then challenged with DA3-MUC1  
(5 x 106 cells/mouse). 4–5 mice were culled each week 
for 5 weeks and microscopic lung metastasis counted. 
Data is presented as mean +/- standard error of the 
mean 
In the second model, BALB/c mice were 
immunised 3 times with either MFP or a con-
trol preparation, M-GST, and challenged with 
5 x 106 DA3-MUC1 tumour cells subcutaneou-
sly. Metastatic lung nodules from 4–6 mice per 
week were examined microscopically for five 
weeks (Figure 1B). Immunisation (prophylactic 
model) with MFP did not protect mice chal-
lenged with DA3-MUC1 from developing lung 
metastases as assessed by the number of lung 
metastases per lung compared to immunised 
control mice.  
From these studies, it was concluded that 
immunisation with MFP could not induce tu-
mour protection in mice challenged with DA3-
MUC1 tumour cells, nor could it offer protec-
tion against an established DA3-MUC1 tu-
mour. These results were in contrast to findings 
in all other MUC1+ tumour models investigated, 
where immunisation with MFP was able to 
successfully induce anti-tumour immunity and 
tumour protection in vivo [14–23, 26, 31]. It 
was hypothesised that DA3-MUC1 tumours 
were not immunogenic due to a decrease in eit-
her costimulatory or MHC molecules on their 
surface. To test these hypotheses, the DA3-
MUC1 tumour was characterised for cell sur-
face molecule expression in vitro and in vivo. 
 
DA3-MUC1 tumour cells express high 
levels of MUC1 but do not express 
MHC class I 
In vitro characterisation of DA3-MUC1. 
The DA3-MUC1 metastatic cell line was ana-
lysed for expression of human MUC1, MHC 
class I and other cell surface markers by flow 
cytometry (Table 1 and Figure 2). MUC1 is 
highly expressed on the surface (> 85%) of 
DA3-MUC1 cells compared to < 2% on non-
transfected parental DA3 cells. In contrast, MHC 
class I expression was considerably decreased 
in both DA3-MUC1 cells (6%) and non trans-
fected DA3 cells (< 3%). There was no detec-
table MHC class II, B7.1, ICAM-2, CD28, 
LFA-2 or CTLA-4 on DA3 or DA3-MUC1 tu-
mour cells (Table 1). Phosphate buffer was 
used as a control for non-specific (Fab’)2 FITC-
conjugate binding . 
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Table 1 
 
In vitro expression of cell surface markers on DA3 and DA3-MUC1 tumour cells cultured with or without 20 ng/ml 
IFN-γ for 72 h. Values represent the percentage of cells positive for each antibody determined by flow cytometry 
 
Cell Surface Markers DA3 (%) DA3-MUC1 (%) DA3-MUC1+IFN-γ (%) 
negative control 1.94 3.12 2.71 
MUC1 3.36 87.73 93.6 
MHC class I 2.98 5.67 76.85 
MHC class II 3.81 3.72 2.01 
B7.1 1.49 3.03 1.67 
ICAM 2 3.70 4.42 2.75 
CD28 4.13 5.22 4.03 
LFA-2 2.27 3.09 2.12 
CTLA-4 4.81 6.09 3.70 
 
 
 
 
Figure 2 – Flow cytometric analysis of in vitro expression of cell surface MUC1 and MHC class I on DA3-MUC1 
cells cultured with or without 20 ng/ml IFNγ for 72 h. The non transfected parental cell line, DA3 was used  
as a control. Phosphate buffer represents negative control binding of FITC-conjugated sheep (Fab’)2  
anti-mouse (1/50) to the tumour cell lines 
 
 
 
 
 
 
In vivo characterisation of DA3-MUC1. 
To characterise the DA3-MUC1 tumour in vivo, 
BALB/c mice were challenged with 5 x 106 
metastatic cells and tumour growth monitored 
for 10 weeks (Figure 3A). Mice had palpable 
subcutaneous tumours after 2–3 weeks and 
were culled after 10 weeks and their subcuta-
neous tumours and lungs removed for tumour 
analysis.  
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Figure 3ABCD – Tumour growth in BALB/c mice challenged with 5 x 106 DA3-MUC1 cells. B. MUC1 and class I 
(H2d) surface expression on DA3-MUC1 tumour cells determined by immunoperoxidase staining; data is presented 
as mean +/- standard error of the mean. DA3-MUC1 tumour cells from the site of a BALB/c subcutaneous tumour 
were stained for, B(i) negative control, B(ii) MUC1 expression using biotinylated-BC2 and B(iii) MHC class I 
expression using biotinylated-34.1.2s. DA3-MUC1 lung metastases were stained for, B(iv) negative control, B(v) 
MUC1 expression using biotinylated-BC2 and B(vi) MHC class I expression using biotinylated-34.1.2s. All images 
are shown at 200x magnification. Non-specific binding of (Fab’)2 conjugate was blocked with 10% BSA in DME and 
control samples were incubated with 10% BSA in DME. C. FACS analysis determining the length of time MHC class 
I expression remained elevated on DA3-MUC1 cells cultured with IFN-γ in vitro. Tumour cells were cultured for 72 h 
with 20 ng/ml IFN-γ to increase MHC class I expression, IFN-γ removed from culture and MHC class I expression 
measured daily. D. Immunoperoxidase staining of DA3-MUC1 cells pre-cultured with IFN-γ and grown in vivo. Mice 
were sacrificed every three days for 10 days, tumours removed, formalin fixed and stained for, D(i) negative control, 
D(ii) MUC1 expression using biotinylated BC2 and D(iii) MHC class I expression using anti-H2d. Phosphate buffer 
was used as a negative control – binding of FITC-conjugated sheep (Fab’)2 anti-mouse (1/50) to the tumour cells 
 
As expected, immunoperoxidase staining 
for MUC1 and MHC class I expression on sub-
cutaneous established DA3-MUC1 tumours 
were similar to that observed in vitro studies. 
DA3-MUC1 tumour cells express high levels 
of MUC1 (75–100% of cells) (Figures 3B) and 
very little, if any, MHC class I (0–15% of 
cells) (Figure 3B i-iii) on their cell surface. 
Lung metastases (macroscopic and microsco-
pic) were observed 30–35 days after a subcuta-
neous injection of 5 x 106 DA3-MUC1 cells, 
however there was no evidence of metastases 
to the liver (data not shown). Immunoperoxi-
dase staining for MUC1 and MHC class I ex-
pression on lung metastases showed MUC1 
expression on ~ 50% of tumour cells in the 
lung but no evidence of MHC class I expres-
sion (Figure 3B iv-vi). 
Elevation of MHC class I expression 
on DA3-MUC1 with IFN-γ 
It is clear that one of the factors hinde-
ring the immunogenicity of the DA3-MUC1 tu-
mour was a decrease in the expression of MHC 
class I. Numerous studies have shown that 
MHC class I expression, and therefore tumour 
immunogencity, can be increased by culturing 
the tumour with recombinant IFN-γ. To deter-
mine whether MHC class I expression could be 
up-regulated on DA3-MUC1 tumour cells, cells 
were cultured with 20 ng/ml vaccinia virus-
IFN-γ for 72 h and MHC class I expression 
determined using flow cytometry. 
DA3-MUC1 expression of MHC class I 
molecules on the tumour surface could be 
greatly increased in vitro by culturing the DA3-
MUC1 cells with IFN-γ (Table 1 and Figure 2). 
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Prior to in vitro culturing with IFN-γ, only 6% 
of DA3-MUC1 cells expressed MHC class I on 
their cell surface (Figure 2), however, after 
culturing cells with IFN-γ for 72 h, 77% of 
DA3-MUC1 tumour cells expressed MHC 
class I (Figure 2) and MUC1 expression still 
remained high (Figure 2).  
To determine the length of time MHC 
class I expression remained elevated on DA3-
MUC1, tumour cells were cultured with IFN-γ 
for 72 h, removed, and then examined daily for 
MHC class I expression (Figure 3C). MHC 
class I expression at 72 h (~ 90%) remained 
elevated (> 70%) for 3 days after the removal 
of the cytokine, after which time the expression 
dropped constantly to plateau at ~ 55% by day 
10.  
To ensure the elevated class I levels ob-
served in vitro could be sustained in vivo, 
DA3-MUC1 cells were cultured with IFN-γ 
and injected subcutaneously into BALB/c 
mice. Tumours were examined on days 4 and 7 
for MHC class I expression by immunoperoxi-
dase staining (Figure 3D). DA3-MUC1 cells 
cultured with IFN-γ expressed high levels of 
MHC class I molecules on 75% of tumour cells 
removed from the subcutaneous site on day 4 
(data not shown), with 50% of tumour cells 
still remaining positive on day 7 (Figure 3D i, 
ii). In vivo expression of MUC1 on the subcu-
taneous tumour was not altered after culturing 
with IFN-γ (Figure 3D iii). Thus, culturing 
DA3-MUC1 cells with IFN-γ increases the 
expression of MHC class I molecules on the 
cell surface for at least 7 days after removal of 
IFN-γ both in vitro and in vivo.  
 
T cells from MFP immunised mice lyse 
IFN-γ treated DA3-MUC1 tumour cell 
targets 
From the data so far, it would appear that 
the DA3-MUC1 tumour is not immunogenic as 
it does not express MHC class I on its surface. 
However, culturing DA3-MUC1 cells with 
IFN-γ increases MHC class I expression, both 
in vitro and in vivo for at least 7 days following 
removal of IFN-γ. We determined whether the 
level of increase in MHC class I on DA3-
MUC1 cells was adequate to be susceptible to 
MUC1 specific cytotoxic T cells (CTL) lysis. 
BALB/c mice were therefore immunised with 
MFP and 7–10 days following the final immu-
nisation, spleens were isolated and CTL were 
able to lyse DA3-MUC1 tumour cells (Figure 
4A). Lysis of DA3-MUC1 tumour cells (trea-
ted with IFN-γ) was similar to that of P815-
MUC1 tumour cells (H-2d+ MUC1+ MHC 
class I+); non MUC1 transfected P815 cells (H-
2d+ MUC1- MHC class I+) were used as a ne-
gative control. Interestingly, without culturing 
with IFN-γ, DA3-MUC1 were lysed by MUC1 
CTL but the response was considerably wea-
ker. Therefore, in vitro MUC1 T cell cytoto-
xicity to DA3-MUC1 tumours increases sub-
stantially with elevated MHC class I expres-
sion. 
 
MHC class I is not sustained to induce 
tumour protection despite induction of 
CTL 
As IFN-γ treated tumours express eleva-
ted levels of MHC class I, and in vitro, MFP 
can stimulate MUC1+ CTL capable of lysing 
DA3-MUC1 target cells (Figure 4A), the anti-
tumour effects of MFP immunisation on DA3-
MUC1 tumours expressing MHC class I was 
investigated in vivo. Mice were immunised 3 
times with either MFP or a control pH 9.0 pho-
sphate buffer and challenged with DA3-MUC1 
tumour cells pre-cultured for 72 h with IFN-γ 
to increase MHC class I expression. BALB/c 
mice were challenged with 5 x 106 DA3-MUC1 
cells with elevated MHC class I expression 
(Figure 4B). Interestingly, a small reduction in 
tumour growth, which correlated with an incre-
ase in MHC class I expression (Figures 2 and 
3), was evident between days 2 and 5 in both 
MFP and control pH 9.0 immunised mice 
(Figure 4B). A significant (p < 0.05) decrease 
in tumour burden was evident in mice immu-
nised with MFP compared to control mice, on 
day 3, suggesting that elevated levels (90–95%) 
of MHC class I expression on DA3-MUC1 
tumour cells may increase their susceptibility 
to CTL lysis. However, no differences in tu-
mour size were noted between MFP and con-
trol mice on any other days, and from day 6 on-
wards, DA3-MUC1 tumours continued to grow 
steadily which corresponded to a steady drop in 
surface MHC class I levels (Figure 3C) as the 
22  Catherine J. Lees, et al. 
 
positive tumour cells lost MHC class I expres-
sion. Thus, elevated class I expression could 
not be sustained in vivo to induce anti-tumour 
CTL responses. 
 
 
 
Figure 4AB – CTL assay of spleen cells from effector 
BALB/c mice immunised with 5 μg MFP, on 51Cr-
labelled DA3-MUC1 cells cultured with IFN-γ for 72 h, 
DA3-MUC1, P815-MUC1 and P815 tumour cell targets. 
B. Subcutaneous tumour growth of DA3-MUC1 cultured 
with IFN-γ in BALB/c mice. Mice (x 10 per group) were 
immunised intraperitoneally on days 0, 7 and 14 with 
either 5 μg MFP (--) or pH 9.0 buffer (--) and 
challenged with 3 x 106 DA3-MUC1 tumour cells 
previously cultured with 20 ng/ml vaccinia virus-IFN-γ 
supernatant (UV inactivated) for 72 h. Data is presented 
as mean +/- standard error of the mean, * p < 0.05 
 
Discussion 
Tumour immunotherapy with mannan 
MUC1 fusion protein (MFP) induces CD8+ cel-
lular immunity and tumour protection in seve-
ral immunogenic MUC1+ tumour models 
(MUC1+ P815, MUC1+ RMA, MUC1+ 3T3) 
([14–23, 26, 31–34]. In these models, the trans-
fection of the tumour cell lines with human 
MUC1 results in the spontaneous rejection of 
the tumours after approximately 15–20 days 
[34]. Yet despite this, there is still a window of 
between 0 and 11 days in which to observe 
either accelerated rejection or an absence of 
tumour growth in immunised mice – the basic 
models with which the MFP anti-tumour im-
mune responses have been described.  
In this study, the aggressive MUC1+ 
metastatic DA3-MUC1 tumour, was investiga-
ted as a model to study MFP immunotherapy as 
it is not spontaneously rejected in mice. Howe-
ver, in contrast to other MUC1+ tumour models 
where MFP immunisation protected mice from 
a tumour challenge, DA3-MUC1 tumours 
grew. This resulted to determined the expres-
sion of various cell surface markers on DA3-
MUC1, required to induce cell mediated immu-
nity. Both in vitro and in vivo studies confir-
med that in contrast to other MUC1+ tumour 
models, DA3-MUC1 has a low expression of 
cell-surface MHC class I which results in redu-
ced immunogenicity in vivo. However, treat-
ment with IFN- in vitro upregulates MHC 
class I expression which can be sustained for 
several days in the absence of IFN- 
Initial immunotherapy studies demonstra-
ted that mice immunised with MFP and then 
challenged with DA3-MUC1 tumours were not 
protected from tumour growth. Similarly in a 
therapy experiment, 3 injections with MFP was 
also inadequate in decreasing tumour burden in 
mice with established DA3-MUC1 tumours. 
These findings were unlike other studies with 
MFP, whereby mice immunised with MFP 
were totally protected against a challenge of 
MUC1+ 3T3 tumours [20, 21] and the indu-
ction of a CD8+ cellular immune response cau-
sed the regression of established 15 day-old 
MUC1+ P815 tumours in DBA/2 mice [31].  
In vitro and in vivo characterisation of 
DA3-MUC1 indicated that the tumour was we-
akly immunogenic because even though high 
surface levels of MUC1 were expressed (> 85%), 
there were low levels of all other cell surface 
molecules needed for T cell activation inclu-
ding MHC class I (< 6%), MHC class II, 
CD80, ICAM-2, CD28, LFA-2 and CTLA-4. 
Similarly, metastatic lung nodules induced by 
DA3-MUC1 again demonstrated MUC1 ex-
pression to be present on 50% of metastatic 
cells but there was no MHC class I expression. 
The absence, or relatively low expression of 
these molecules on the tumour cell surface 
causes anergy in any activated T cells and is an 
effective mechanism many tumours have evol-
ved to evade the immune system [7]. 
However, tumour immunogenicity can be 
successfully increased by up-regulating the 
expression of these molecules (particularly 
MHC and costimulatory molecules) by either 
gene transfection or culturing with cytokines – 
specifically IFN-γ [5, 6, 9, 12]. Therefore, to 
increase the expression of MHC class I on 
DA3-MUC1 cells, cells were cultured with 
IFN-γ. Culturing DA3-MUC1 with IFN-γ in-
creased expression of MHC class I from < 16% 
to > 90% after 72 h. The MHC class I expres-
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sion remained elevated for several days before 
declining to 50% one week after the cytokine 
was removed from culture. In vivo studies of 
MHC class I expression on DA3-MUC1 after 
IFN-γ culturing, revealed a similar pattern 
whereby levels previously not detected in a 
subcutaneous tumour, were elevated to 50–
75% of cells expressing MHC class I four days 
later, and still present on day 7. Interestingly, 
culturing DA3-MUC1 with IFN-γ did not 
increase cell surface expression of MHC class 
II, CD80, ICAM-2, CD28, LFA-2 or CTLA-4 
as had been previously reported in other 
tumour models [35].  
Following the up-regulation of MHC 
class I on the surface of DA3-MUC1 tumours, 
MUC1 specific CTL isolated from the spleen 
of MFP immunised mice could lyse DA3-
MUC1 tumour cells cultured with IFN-γ, but 
not DA3-MUC1 cells which were not cultured 
with IFN-γ. This result was considerably higher 
than untreated tumour cells, demonstrating that 
DA3-MUC1 immunogenicity is increased in 
the presence of MHC class I, and can be lysed 
by MUC1 restricted CTL in vitro.  
 The lack of an effective anti-tumour 
response in DA3-MUC1 tumours is, in part, a 
result of the down-regulation in MHC class I 
expression which can be overcome by culturing 
the tumour with IFN-γ. As culturing with IFN-γ 
only temporarily increases MHC class I expres-
sion, it is suggested that future studies in this 
model would focus on the transfection of the 
IFN-γ gene into DA3-MUC1 cells. Alterna-
tively, the decrease in DA3-MUC1 immunoge-
nicity may also be a result of tumour-reactive T 
cells receiving inadequate costimulation thro-
ugh the absence of the costimulatory molecules 
B7-1 and B7-2. This again can be over come 
through transfection with these molecules [36, 
37] and is also suggested for future immuno-
therapy studies with MFP. Furthermore, we 
have not investigated whether other relevant 
receptors may not be expressed by DA3-MUC1 
cells. Finally, DA3-MUC1 cells could be used 
as a model to study other mechanisms and lysis 
where MHC class I is not required, such as, 
NK cell lysis.  
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Имунотерапија која користи муцин 1 
(MUC1) поврзан со оксидиран манан (MFP) 
беше испитувана кај агресивен метастатски тумор 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MUC1+, DA3-MUC1, затоа што, за разлика од 
многу туморски модели на MUC1+, DA3-MUC1 
не е спонтано одбиен кај глувците, што го прави 
алтернативен модел за студии на имунотера-
пија. Исто така, клетките DA3-MUC1 се от-
порни на лизирање од анти-MUC1 цитотокси-
чни Т-клетки (CTLs). Неможноста туморите 
DA3-MUC1 да бидат отфрлени кај глувците 
како и вакцинацијата за MUC1 беше припишана 
на недостатокот на експресија на молекулите на 
MHC од класа I на површината на туморските 
клетки. Ин витро и ин виво анализата на пот-
кожните тумори и метастази на белите дробови 
покажа дека туморските клетки DA3-MUC1 
имаат ниска експресија (< 6%) на MHC класа I, 
кои може да се регулираат (> 90%) по кул-
тивирање со IFN-γ. Резултатите од анализата на 
проточната цитометрија и боењето со имуно-
пероксидаза посочи дека ин витро нагорната ре-
гулација на MHC класа I може да се одржува до 
седум дена ин виво, без засегање на нивоата на 
експресија на MUC1 антигенот. Интересно, 
MUC1 специфичните CTL кои ин витро ги лизи-
раат DA3-MUC1 целите беа воведени кај вакци-
нирани глувци од MFP, но не успеаја да ги 
заштитат глувците од туморскиот предизвик на 
DA3-MUC1. Овие резултати ја нагласуваат важ-
носта на молекулите на MHC од класа I во пот-
тикнувањето на антитуморскиот имунитет и 
имуниот одговор на MFP. 
 
Клучни зборови: MUC1, MHC класа I, интерферон-
гама, тумор, имунотерапија 
 
